PMCB — Pharmacyte Biotech Share News
0.000.00%
Last trade - 00:00Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer
Brief: Pharmacyte Biotech To Implement Second $10-Million Share Repurchase Plan
Brief: Pharmacyte Biotech reaches cooperation agreement with Iroquois Capital
Brief: Iroquois Files Preliminary Consent Materials To Reconstitute Board Of Directors At Pharmacyte Biotech Inc
Brief: Pharmacyte Biotech Commences First Phase Of Two-Phase Pig Study
Brief: Pharmacyte Biotech Announces Preliminary Unaudited Financial Results For Fiscal Year 2022
Brief: Iroquois Capital Commences Consent Solicitation To Reconstitute Pharmacyte Biotech Board Of Directors
Brief: PharmaCyte Biotech Announces Additional Quality Control Assay And Confirms Stability Of CypCap Cells
Brief: Iroquois Capital Management Nominated Slate Of 7 Director Candidates For Election To Pharmacyte Biotech Board At Co's 2022 Annual Meeting
Brief: PharmaCyte Biotech Issues Follow-Up Response To Iroquois Capital’S Second Letter On June 9
Brief: Iroquois Capital Delivers Open Letter To Pharmacyte Biotech Board Of Directors
Brief: Pharmacyte Biotech Issues Response To Iroquois Capital Letter
Brief: Pharmacyte Biotech To Implement $10-Million Share Repurchase Program
Brief: PharmaCyte Biotech Begins Studies To Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
Brief: Iroquois Capital Delivers Open Letter To Pharmacyte Biotech Board Of Directors
Brief: PharmaCyte Announces Tests Results For Pancreatic Cancer Clinical Trial Product Candidate